| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
Clinical relevance of the use of Dentoxol® for oral mucositis induced by radiotherapy: A phase II clinical trial
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Sebastián Solé, Sergio Becerra, Claudia Carvajal, Piero Bettolli, Hernán Letelier, Alejandro Santini, Lorena Vargas, Alexander Cifuentes, Francisco Larsen, Natalia Jara, Jorge Oyarzún, Eva Bustamente, Benjamín Martínez, David Rosenberg and Tomas Galván |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Sebastián Solé, MD, Assistant Professor, Department of Radiotherapy, Radiomedicine Institute, Américo Vespucio Norte 1314 Vitacura, 8380455, Santiago, Chile. sebasole@gmail.com |
| Key Words |
Clinical trial; Dentoxol; Oral mucositis; Prevention; Radiotherapy; Treatment |
| Core Tip |
Oral mucositis associated with cancer therapy is a frequent complication. Dentoxol® is a medical solution that has been shown to prevent severe oral mucositis. The clinical significance of Dentoxol® was measured using the results obtained in a randomized controlled clinical trial previously conducted by the same group of researchers. The data obtained show that the clinical impact of Dentoxol® on oral mucositis justifies its incorporation into clinical protocols as a complement to cancer therapy to prevent and/or treat oral mucositis. |
| Publish Date |
2022-10-20 06:46 |
| Citation |
Solé S, Becerra S, Carvajal C, Bettolli P, Letelier H, Santini A, Vargas L, Cifuentes A, Larsen F, Jara N, Oyarzun J, Bustamante E, Martinez B, Rosenberg D, Galván T. Clinical relevance of the use of Dentoxol® for oral mucositis induced by radiotherapy: A phase II clinical trial.. World J Clin Oncol 2022; 13(10): 813-821 |
| URL |
https://www.wjgnet.com/2218-4333/full/v13/i10/813.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v13.i10.813 |
